胃癌患者血浆TAFI及TAT的变化及其临床意义

Levels and Clinical Significances of Thrombin Activated Fibrinolysis Inhibitor (TAFI) and Thrombin-antithrombin Complex (TAT) in Gastric Cancer

目的探讨胃癌患者血浆凝血酶激活的纤溶抑制物(thrombin activated fibrinolysis inhibitor,TAFI)和凝血酶-抗凝血酶复合物(thrombin-antithrombin complex,TAT)水平的变化及其与胃癌的关系。方法收集原发性胃癌患者106例为实验组。同时,收集体检健康者30例为对照组。采用酶联免疫吸附双抗体夹心(ELISA)法定量测定血浆中凝血酶激活的纤溶抑制物抗原(TAFI:Ag)及TAT水平。结果实验组血浆TAFI:Ag及TAT水平分别为(30.0±2.5)μg/m L及(36.3±3.4)ng/m L,对照组血浆TAFI:Ag及TAT水平分别为(22.5±2.5)μg/m L及24.5±2.5 ng/m L,有显著性差异(P<0.05)。胃癌患者TAFI抗原及TAT水平随临床分期的进展而增高,Spearman秩相关分析提示,其与术后病理分期呈正相关,相关系数分别为0.814及0.881。用ROC曲线研究TAFI抗原和TAT两项指标的检验效能显示:TAFI抗原的临界值为26.25μg/m L(AUC=0.915,P<0.05);TAT的临界值为29.15 ng/m L(AUC=0.852,P<0.05)。结论胃癌患者体内TAFI及TAT水平均显著升高,并与胃癌病理分期呈正相关,提示其作为胃癌诊治的辅助实验室指标或有可观的应用价值。

Objective To study the levels of thrombin activated fibrinolysis inhibitor （TAFI） and thrombin-antithrombin complex（TAT） in gastric cancer and their relationships with gastric cancer. Methods 106 cases of gastric cancer were the experimental group, and 30 healthy individuals were the control group. ELISA method was used to detect the levels of TAFI ： Ag and TAT. Results The level of TAFI ： Ag and TAT in the experimental group respectively were 30.0 ±2.5 μg/mL and 36.3 ±3.4 ng/mL;while the level of TAFI ： Ag and TAT in the control group were 22.5± 2.5 μg/mL and 24.5 ± 2.5 ng/mL, the differences were statistically significant （ P 〈 0. 05 ）. The levels of TAFI ： Ag and TAT in the experimental group increased along with the development of gastric cancer. Spearman rank correlation test revealed that the levels of TAFI and TAT were positively correlated with pathological stage, correlation coefficients were 0. 814 and 0. 881. The cutoff of TAFI：Ag was 26.25 μg/mL（ AUC = 0.915, P 〈 0.05 ） , and the cutoff of TAT was 29.15ng/mL（ AUC = 0. 852, P 〈 0.05 ）. Conclusion The levels of TAFI and TAT in patients with gastric cancer are higher and are positively correlated with pathological stage. TAFI and TAT can be useful lab test indexes for gastric cancer.